InsidersTradesSigma
Follow the Sierra Oncology, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Sierra Oncology, Inc. has published 33 reports. The latest transaction was disclosed on 1 July 2022 (Disposition). Among the most active insiders: Turner William D.. Every trade is free.
33
Insider Decl.
n/a
Thresholds
€47m
6 ops.
Buy Volume
€381m
9 ops.
Sell Volume
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 July 2022
Declarations33 total
5,000 shares@ US$55.0078.2% of flowCommon StockSEC:0001209191-22-040252:0
1,511,362 shares@ US$55.0090.1% of flowCommon StockSEC:0001209191-22-040281:0
10,000 shares@ US$55.00100.0% of flowCommon StockSEC:0001209191-22-040274:0
1,650 shares@ US$55.00100.0% of flowCommon StockSEC:0001209191-22-040258:0
1,314,127 shares@ US$55.0091.0% of flowCommon Stock, $0.001 par valueSEC:0001493152-22-018397:0
161,712 shares@ US$55.0017.8% of flowCommon StockSEC:0001213900-22-036724:0
13,500 shares@ US$55.0075.6% of flowCommon StockSEC:0001209191-22-040255:0
1,511,362 shares@ US$55.0090.1% of flowCommon StockSEC:0001209191-22-040288:0
2,735,853 shares@ US$55.0074.2% of flowCommon StockSEC:0001209191-22-040279:0
175,000 shares0Common StockSEC:0000899243-22-016052:0
100 shares@ US$12.050.3% of flowCommon StockSEC:0001209191-22-023656:0
2,000 shares@ US$13.0417.1% of flowCommon StockSEC:0001209191-22-022692:0
100 shares@ US$12.050.3% of flowCommon StockSEC:0001209191-22-020521:0
3,453 shares@ US$12.0510.6% of flowCommon StockSEC:0001209191-22-019748:0
2,000 shares@ US$13.0416.9% of flowCommon StockSEC:0001209191-22-016214:0
10,000 shares@ US$12.0529.5% of flowCommon StockSEC:0001209191-22-007719:0
2,000 shares@ US$13.0416.4% of flowCommon StockSEC:0001209191-22-007183:0
175,000 shares@ US$27.0021.2% of flowCommon StockSEC:0000899243-22-004271:0
Canonical exit: 3 May 2022 (T+90)
175,000 shares@ US$27.0021.2% of flowCommon StockSEC:0000899243-22-004270:0
Canonical exit: 3 May 2022 (T+90)
287,471 shares@ US$13.204.5% of flowCommon Stock, $0.001 par valueSEC:0000905718-22-000178:0
287,471 shares@ US$13.2050.0% of flowCommon Stock, $0.001 par valueSEC:0000905718-22-000177:0
800,000 shares@ US$27.0040.5% of flowCommon StockSEC:0001213900-22-004647:0
Canonical exit: 1 May 2022 (T+90)
800,000 shares@ US$27.0010.0% of flowCommon StockSEC:0001209191-22-005748:0
Canonical exit: 1 May 2022 (T+90)
2,000 shares@ US$13.0416.6% of flowCommon StockSEC:0001209191-22-005434:0
374,962 shares@ US$13.205.0% of flowCommon StockSEC:0001209191-22-005512:0
25 of 33 declarations
关于 Sierra Oncology, Inc.
Sierra Oncology, Inc. 是一家在美国纳斯达克（NASDAQ）上市的生物制药公司，股票代码为 SRRA，后被葛兰素史克（GSK）收购，交易于 2022 年 7 月 1 日完成。该公司在美国注册成立，总部位于加利福尼亚州圣马特奥。从股权分析的角度来看，Sierra Oncology 符合专业生物技术公司的特征：一个围绕少数高价值临床资产而非广泛商业产品组合构建的专注开发阶段平台。([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-sierra-oncology/?utm_source=openai)) 其核心业务是开发罕见癌症的靶向疗法，特别侧重于血液肿瘤学。主要资产是 momelotinib，这是一种针对骨髓纤维化患者，特别是贫血患者的后期研究性药物。这种治疗重点很重要，因为骨髓纤维化是一种罕见的血癌，具有显著的症状负担和有限的治疗选择，使得差异化的作用机制在商业和临床上都非常重要。因此，Sierra 的价值主张集中于临床执行、监管进展和最终的标签差异化，而不是经常性产品销售或广泛的运营规模。([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-sierra-oncology/?utm_source=openai)) 从历史来看，Sierra Oncology 发展成为一家以研究为主导的生物技术公司，其活动主要集中在美国，并通过监管备案途径扩展到欧洲。该公司 2022 年围绕 momelotinib 的监管工作成为吸引大型制药公司战略兴趣的关键催化剂。葛兰素史克宣布达成协议，以约 1.9 billion 美元收购 Sierra Oncology，并随后确认完成收购。这笔交易有效地实现了该公司主要临床资产的货币化，并结束了 Sierra Oncology 作为独立上市发行人的历史。([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/?utm_source=openai)) 对于法国、比利时和瑞士的投资者而言，该案例主要作为历史性的美国生物技术公司案例集而非当前的运营股权故事具有重要意义。该公司在美国纳斯达克上市，其市场相关性主要来自一个主要项目 momelotinib，以及骨髓纤维化护理贫血领域中蕴含的战略选择权。Sierra Oncology 没有商业制药集团多元化的产品组合；相反，它是一家以管线为中心的专业公司，其竞争地位取决于临床差异化、监管里程碑以及合作伙伴或收购方的兴趣。在葛兰素史克收购之后，其后续市场相关性主要局限于历史 SEC 记录，包括 Form 4 等内部人交易备案，而非持续的公开市场运营。([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/?utm_source=openai))
